复星医药(600196.SH)：复宏汉霖已刊发招股章程 H股发行价每股49.6港元-57.8港元
格隆汇9月12日丨复星医药(600196.SH)公布，就建议分拆及上市，复宏汉霖于2019年9月12日刊发招股章程，载有(其中包括)：(1)全球发售中将提呈发售的复宏汉霖H股数目详情、发售价范围及全球发售的其他详情、及(2)有关复宏汉霖的若干业务及财务资料。
复宏汉霖招股章程可自2019年9月12日起于香港联交所网站查阅及下载。该等招股章程印刷本可于2019年9月12日上午9点整至2019年9月17日中午12点整的正常营业时间于以下文件列明的指定地点免费索取：(1)复宏汉霖于2019年9月11日于香港联交所网站作出的混合媒介要约公告、(2)复宏汉霖于2019年9月12日于香港联交所网站刊发的正式通告、及(3)复宏汉霖招股章程。
如复宏汉霖招股章程所披露，根据全球发售将提呈发售的复宏汉霖H股股份总数将为6469.54万股(假设超额配售权未获行使)、占紧随全球发售完成后复宏汉霖已发行股份总数的约12%，以及7439.97万股(假设超额配售权获悉数行使)、占紧随全球发售完成后复宏汉霖已发行股份总数的约13.56%。
全球发售中的复宏汉霖H股股份发售价预期将不低于每股49.60港元、不超过每股57.80港元(不包括经纪佣金、证监会交易征费及香港联交所交易费)。
基于根据全球发售将提呈发售的复宏汉霖H股股份的数目及上述预期发售价范围，如果全球发售落实进行：
(1)复宏汉霖的市值将为约267.408亿港元至约311.616亿港元(假设超额配售权未获行使)及约272.221亿港元至约317.225亿港元(假设超额配售权获悉数行使)；
(2)全球发售的规模将为约32.09亿港元至约37.39亿港元(假设超额配售权未获行使)及约36.90亿港元至约43亿港元(假设超额配售权获悉数行使)；
(3)紧随全球发售完成后，公司(通过控股子公司)将间接持有约53.76%的复宏汉霖股份(假设超额配售权未获行使)，以及约52.81%的复宏汉霖股份(假设超额配售权获悉数行使)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
